{"id":34261,"date":"2025-05-27T16:47:10","date_gmt":"2025-05-27T08:47:10","guid":{"rendered":"https:\/\/flcube.com\/?p=34261"},"modified":"2025-05-27T16:47:11","modified_gmt":"2025-05-27T08:47:11","slug":"drug-farm-and-amoytop-biotech-collaborate-on-df-006-for-hbv-and-hcc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34261","title":{"rendered":"Drug Farm and Amoytop Biotech Collaborate on DF-006 for HBV and HCC"},"content":{"rendered":"\n

Sino-US biotech Drug Farm announced the signing of an option agreement with Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278<\/a>) to collaborate on the clinical development of DF-006 for the treatment of hepatitis B virus (HBV) and hepatocellular carcinoma (HCC) in Greater China (Mainland China, Hong Kong, Macau, and Taiwan). This strategic partnership aims to leverage the strengths of both companies to advance the clinical development of this promising therapeutic agent.<\/p>\n\n\n\n

DF-006 Mechanism and Potential<\/strong>
DF-006 is an oral alpha-kinase 1 (ALPK1) agonist that effectively activates the innate immunity of the liver. This mechanism of action positions DF-006 as a novel therapeutic approach for patients with HBV and HCC. Preclinical studies have shown that the combination of DF-006 and alpha-interferon enhances the anti-HBV effect, highlighting its potential as a valuable addition to existing treatment regimens.<\/p>\n\n\n\n

Clinical Development Progress<\/strong>
The drug has demonstrated positive anti-HBV activity in multi-dose escalation studies. It has completed single-dose and multi-dose escalation studies in healthy subjects, providing a solid foundation for further clinical development. This progress underscores Drug Farm’s commitment to advancing innovative therapies for liver-related diseases.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Sino-US biotech Drug Farm announced the signing of an option agreement with Xiamen-based Amoytop Biotech…<\/p>\n","protected":false},"author":1,"featured_media":34262,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[470,16,1652,1232,89],"class_list":["post-34261","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-amoytop-biotech","tag-cancer","tag-drug-farm","tag-sha-688278","tag-viral-hepatitis"],"yoast_head":"\nDrug Farm and Amoytop Biotech Collaborate on DF-006 for HBV and HCC - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sino-US biotech Drug Farm announced the signing of an option agreement with Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) to collaborate on the clinical development of DF-006 for the treatment of hepatitis B virus (HBV) and hepatocellular carcinoma (HCC) in Greater China (Mainland China, Hong Kong, Macau, and Taiwan). This strategic partnership aims to leverage the strengths of both companies to advance the clinical development of this promising therapeutic agent.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34261\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Drug Farm and Amoytop Biotech Collaborate on DF-006 for HBV and HCC\" \/>\n<meta property=\"og:description\" content=\"Sino-US biotech Drug Farm announced the signing of an option agreement with Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) to collaborate on the clinical development of DF-006 for the treatment of hepatitis B virus (HBV) and hepatocellular carcinoma (HCC) in Greater China (Mainland China, Hong Kong, Macau, and Taiwan). This strategic partnership aims to leverage the strengths of both companies to advance the clinical development of this promising therapeutic agent.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34261\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-27T08:47:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-27T08:47:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2717.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1440\" \/>\n\t<meta property=\"og:image:height\" content=\"810\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34261#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34261\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Drug Farm and Amoytop Biotech Collaborate on DF-006 for HBV and HCC\",\"datePublished\":\"2025-05-27T08:47:10+00:00\",\"dateModified\":\"2025-05-27T08:47:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34261\"},\"wordCount\":195,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34261#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2717.webp\",\"keywords\":[\"Amoytop Biotech\",\"Cancer\",\"Drug Farm\",\"SHA: 688278\",\"Viral hepatitis\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34261#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34261\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34261\",\"name\":\"Drug Farm and Amoytop Biotech Collaborate on DF-006 for HBV and HCC - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34261#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34261#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2717.webp\",\"datePublished\":\"2025-05-27T08:47:10+00:00\",\"dateModified\":\"2025-05-27T08:47:11+00:00\",\"description\":\"Sino-US biotech Drug Farm announced the signing of an option agreement with Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) to collaborate on the clinical development of DF-006 for the treatment of hepatitis B virus (HBV) and hepatocellular carcinoma (HCC) in Greater China (Mainland China, Hong Kong, Macau, and Taiwan). This strategic partnership aims to leverage the strengths of both companies to advance the clinical development of this promising therapeutic agent.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34261#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34261\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34261#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2717.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2717.webp\",\"width\":1440,\"height\":810,\"caption\":\"Drug Farm and Amoytop Biotech Collaborate on DF-006 for HBV and HCC\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34261#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Drug Farm and Amoytop Biotech Collaborate on DF-006 for HBV and HCC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Drug Farm and Amoytop Biotech Collaborate on DF-006 for HBV and HCC - Insight, China's Pharmaceutical Industry","description":"Sino-US biotech Drug Farm announced the signing of an option agreement with Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) to collaborate on the clinical development of DF-006 for the treatment of hepatitis B virus (HBV) and hepatocellular carcinoma (HCC) in Greater China (Mainland China, Hong Kong, Macau, and Taiwan). This strategic partnership aims to leverage the strengths of both companies to advance the clinical development of this promising therapeutic agent.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34261","og_locale":"en_US","og_type":"article","og_title":"Drug Farm and Amoytop Biotech Collaborate on DF-006 for HBV and HCC","og_description":"Sino-US biotech Drug Farm announced the signing of an option agreement with Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) to collaborate on the clinical development of DF-006 for the treatment of hepatitis B virus (HBV) and hepatocellular carcinoma (HCC) in Greater China (Mainland China, Hong Kong, Macau, and Taiwan). This strategic partnership aims to leverage the strengths of both companies to advance the clinical development of this promising therapeutic agent.","og_url":"https:\/\/flcube.com\/?p=34261","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-27T08:47:10+00:00","article_modified_time":"2025-05-27T08:47:11+00:00","og_image":[{"width":1440,"height":810,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2717.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34261#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34261"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Drug Farm and Amoytop Biotech Collaborate on DF-006 for HBV and HCC","datePublished":"2025-05-27T08:47:10+00:00","dateModified":"2025-05-27T08:47:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34261"},"wordCount":195,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34261#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2717.webp","keywords":["Amoytop Biotech","Cancer","Drug Farm","SHA: 688278","Viral hepatitis"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34261#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34261","url":"https:\/\/flcube.com\/?p=34261","name":"Drug Farm and Amoytop Biotech Collaborate on DF-006 for HBV and HCC - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34261#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34261#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2717.webp","datePublished":"2025-05-27T08:47:10+00:00","dateModified":"2025-05-27T08:47:11+00:00","description":"Sino-US biotech Drug Farm announced the signing of an option agreement with Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) to collaborate on the clinical development of DF-006 for the treatment of hepatitis B virus (HBV) and hepatocellular carcinoma (HCC) in Greater China (Mainland China, Hong Kong, Macau, and Taiwan). This strategic partnership aims to leverage the strengths of both companies to advance the clinical development of this promising therapeutic agent.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34261#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34261"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34261#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2717.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2717.webp","width":1440,"height":810,"caption":"Drug Farm and Amoytop Biotech Collaborate on DF-006 for HBV and HCC"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34261#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Drug Farm and Amoytop Biotech Collaborate on DF-006 for HBV and HCC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2717.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34261"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34261\/revisions"}],"predecessor-version":[{"id":34263,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34261\/revisions\/34263"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34262"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}